Related Experiment Video
Updated: Jun 6, 2025
Preparation of Exosomes for siRNA Delivery to Cancer Cells
Published on: December 5, 2018
Exosome-based strategy against colon cancer using small interfering RNA-loaded vesicles targeting soluble a
Hyung-Jin Kim1, Do Sang Lee2,3, Jung Hyun Park1,3
1Department of Surgery, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 03312, South Korea.
Background:
Recent advancements in nanomedicine have highlighted the potential of exosome (Ex)-based therapies, utilizing naturally derived nanoparticles, as a novel approach to targeted cancer treatment.
Aim:
To explore the targetability and anticancer effectiveness of small interfering peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 RNA (siPIN1)-loaded soluble a proliferation-inducing ligand (sAPRIL)-targeted Exs (designated as tEx[p]) in the treatment of colon cancer models.
Methods:
tEx was generated by harvesting conditioned media from adipose-derived stem cells that had undergone transformation using pDisplay vectors encoding sAPRIL-binding peptide sequences. Subsequently, tEx[p] were created by incorporating PIN1 siRNA into the tEx using the Exofect kit. The therapeutic efficacy of these Exs was evaluated using both in vitro and in vivo models of colon cancer.
Results:
The tEx[p] group exhibited superior anticancer effects in comparison to other groups, including tEx, Ex[p], and Ex, demonstrated by the smallest tumor size, the slowest tumor growth rate, and the lightest weight of the excised tumors observed in the tEx[p] group (P < 0.05). Moreover, analyses of the excised tumor tissues, using western blot analysis and immunohistochemical staining, revealed that tEx[p] treatment resulted in the highest increase in E-cadherin expression and the most significant reduction in the mesenchymal markers Vimentin and Snail (P < 0.05), suggesting a more effective inhibition of epithelial-mesenchymal transition tEx[p], likely due to the enhanced delivery of siPIN1.
Conclusion:
The use of bioengineered Exs targeting sAPRIL and containing siPIN1 demonstrated superior efficacy in inhibiting tumor growth and epithelial-mesenchymal transition, highlighting their potential as a therapeutic strategy for colon cancer.
Insights
Engineered exosomes targeting soluble a proliferation-inducing ligand (sAPRIL) and loaded with small interfering peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 RNA (siPIN1) effectively inhibited colon cancer growth and epithelial-mesenchymal transition in preclinical models.
Area of Science:
- Nanomedicine
- Cancer Therapy
- Molecular Biology
Background:
- Exosome (Ex)-based therapies leverage naturally derived nanoparticles for targeted cancer treatment.
- Recent nanomedicine advancements show promise for exosome applications in oncology.
Purpose of the Study:
- To investigate the targeting capability and anticancer efficacy of soluble a proliferation-inducing ligand (sAPRIL)-targeted exosomes loaded with small interfering peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 RNA (siPIN1) (tEx[p]).
- To evaluate tEx[p] in colon cancer models for potential therapeutic applications.
Main Methods:
- Engineered exosomes (tEx) were produced from modified adipose-derived stem cells expressing sAPRIL-binding peptides.
- PIN1 siRNA was encapsulated into tEx using the Exofect kit to create tEx[p].
- Therapeutic effects were assessed using in vitro and in vivo colon cancer models.
Main Results:
- tEx[p] significantly inhibited tumor growth, evidenced by smaller tumor size and weight compared to control groups (tEx, Ex[p], Ex).
- Western blot and immunohistochemical analyses showed increased E-cadherin and decreased Vimentin and Snail expression in tEx[p]-treated tumors.
- Results indicate effective inhibition of epithelial-mesenchymal transition, likely due to enhanced siPIN1 delivery.
Conclusions:
- Bioengineered exosomes targeting sAPRIL and delivering siPIN1 show significant potential for colon cancer therapy.
- These engineered exosomes effectively inhibit tumor growth and epithelial-mesenchymal transition.
- The study highlights a promising nanomedicine strategy for colon cancer treatment.
Related Concept Videos
01:36Overview of Exosomes
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...